Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-2494 in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs ACE 2494 (Primary)
- Indications Musculoskeletal disorders
- Focus Adverse reactions
- Sponsors Acceleron Pharma
- 02 Jul 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2019.
- 02 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.
- 04 Apr 2019 Status changed from active, no longer recruiting to completed, according to an Acceleron Pharma media release.